Lv75
4788 积分 2021-10-09 加入
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
1小时前
待确认
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies
3天前
已完结
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
4天前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
8天前
已完结
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
8天前
已完结
Hitting the target in HER2 mutant cancers
8天前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
8天前
已完结
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management
10天前
已完结
Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα
15天前
已完结
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
21天前
已完结
皖公网安备34019202002308
